哈药股份(600664.SH)：拉西地平片通过仿制药一致性评价

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (600664.SH) announced that its subsidiary, Sanjing Ming Shui Pharmaceutical Co., Ltd., received a drug supplement approval notice from the National Medical Products Administration for Lercanidipine tablets, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved drug, Lercanidipine, is a highly selective calcium channel blocker that effectively dilates peripheral small arteries, reducing peripheral vascular resistance and lowering blood pressure [1] - Lercanidipine can be used alone or in combination with other antihypertensive medications such as beta-blockers, diuretics, and angiotensin-converting enzyme inhibitors for the treatment of hypertension [1]